Correction: Converting an immunologically “cold” tumor: Exceptional response to cadonilimab plus chemotherapy in microsatellite-stable pancreatic cystadenocarcinoma - Takeaways - MDSpire

Correction: Converting an immunologically “cold” tumor: Exceptional response to cadonilimab plus chemotherapy in microsatellite-stable pancreatic cystadenocarcinoma

  • By

  • Chunxiao Ni

  • Jiaju Xu

  • Yu Pang

  • June 10, 2026

  • 0 min

Share

  • 1

    The article discusses a correction regarding authorship in a study on pancreatic cystadenocarcinoma.

  • 2

    Jiaju Xu was mistakenly omitted as an equal contributing author in the original publication.

  • 3

    The study focuses on the response to cadonilimab combined with chemotherapy in treating a specific tumor type.

  • 4

    The original article was published in Frontiers in Immunology in 2026.

  • 5

    The DOI for the corrected article is 10.3389/fimmu.2026.1735785.

Original Source(s)

Correction: Converting an immunologically “cold” tumor: Exceptional response to cadonilimab plus chemotherapy in microsatellite-stable pancreatic cystadenocarcinoma

  • by Chunxiao Ni, Jiaju Xu, Yu Pang

  • June 10, 2026

Related Content

Challenges and emerging strategies for genome-wide evaluation of loss of imprinting in cancer

Angiosarcoma in a soft tissue sarcoma cohort: real-world patterns and outcomes

BCOR-CCNB3 fusion–positive sarcoma treated with chemotherapy and carbon-ion radiotherapy: a case report of long-term disease control of a cervical spine case with a 12-year follow-up